Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of flubromazepam can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of flubromazepam can be broken down into several components which progressively intensify proportional to dosage. The general head space of flubromazepam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Flubromazepam is described as extremely psychologically addictive. Compulsive redosing is common, driven by rapid anxiety relief followed by quick offset. Memory suppression can lead to users forgetting prior doses, potentially resulting in dangerous amnesic blackout states.
Flubromazepam is extremely physically addictive with severe withdrawal risk. Abrupt discontinuation after regular use can be life-threatening, potentially causing seizures or death. Safe cessation requires gradual tapering over weeks.
Flubromazepam likely has low toxicity relative to dose when used alone. However, fatal overdose may occur when combined with other depressants such as alcohol, opioids, or barbiturates due to synergistic respiratory depression.
Paradoxical reactions including aggression, violent behavior, and loss of impulse control occur rarely (below 1% in the general population), with greater frequency among recreational abusers, individuals with mental disorders, children, and those on high-dose regimens.
Flubromazepam has anticonvulsant properties during active use. Paradoxical increased seizures are rarely reported in epileptic individuals. Abrupt discontinuation after regular use poses significant seizure risk, as benzodiazepine withdrawal seizures can be life-threatening.
Flubromazepam is a benzodiazepine derivative first synthesized in 1960. Despite being developed during a period of active benzodiazepine research that produced many compounds which would eventually reach clinical use, flubromazepam was never marketed and received no further scientific attention for…
Controlled as a benzodiazepine under Schedule IV of the Controlled Drugs and Substances Act.
Classified as a Schedule III controlled substance since 2017.
Classified as a controlled drug under national legislation. Possession, production, supply, and importation are illegal.
No federal scheduling under the Controlled Substances Act. Virginia has independently classified flubromazepam as a Schedule I controlled substance under state law.
Listed in Anlage II of the Betäubungsmittelgesetz (Narcotics Act) since November 21, 2015. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing are prohibited without a license.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics regulations.
Controlled under the Misuse of Drugs Act 1971 as of May 31, 2017. Possession, production, and supply are prohibited.
14 sources cited
